ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi And Regulus Sign RNA Pact

by Ann M. Thayer
June 28, 2010 | APPEARED IN VOLUME 88, ISSUE 26

Regulus Therapeutics will work with Sanofi-Aventis to develop drugs based on microRNAs, a class of small noncoding RNAs that regulate gene expression. Sanofi will pay $25 million up front and make a $10 million investment in the company in the future. All told, Regulus could receive up to $750 million in fees, R&D funding, and potential milestone payments. The partners will work on four initial micro­RNA targets, and Sanofi has the option to develop others. Isis Pharmaceuticals and Alnylam Pharmaceuticals are joint owners of Regulus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment